findmyKOL

Rachel Kuchtey, MD, PhD

Basic profile

Vanderbilt University

ORCIDNPI
RegionNashville, TN · SoutheastSpecialtyOphthalmologyFocusOphthalmology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2024Online presenceNot yet checkedPayments2021 onwardNIH funding2010–2025

Rachel Kuchtey is an Ophthalmology physician affiliated with Vanderbilt University. OpenAlex indexes 94 publications with 1,789 citations (h-index 20).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
94publications

Distinct works indexed by OpenAlex, matched via ORCID.

1,789citations

Total citations across indexed works.

20h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
2companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments
1NIH grants · 2010–2025

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

3601 The Vanderbilt Clinic
Nashville, TN 372320001

Telephone

615-322-3000

Provider last certified this registry record 5 Feb 2026.

View the NPPES registry record

Industry payments

2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Sensory organs

    85.3%
    Prostaglandin Analog33.2%
    Latanoprost88%Lumigan9%Travoprost3%
    Part D215 patients
    Carbonic Anhydrase Inhibitor25.5%
    Dorzolamide-Timolol66%Dorzolamide Hcl20%Simbrinza8%Brinzolamide2%Azopt2%Acetazolamide Er2%
    Part D<11 patients

    + 5 more classes in this area

  • Musculoskeletal

    4%
    Cyclooxygenase Inhibitor4%
    Ketorolac Tromethamine100%
    Part D79 patients
  • Anti-infectives

    3.9%
    Fluoroquinolone Antibacterial3.2%
    Moxifloxacin100%
    Part D54 patients
    Tetracycline-class Drug0.7%
    Doxycycline Monohydrate100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

1 NIH research award on record, funded 20102025 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”